Forskolin

Forskolin

Forskolin is a naturally occurring labdane-type diterpenoid compound isolated from the root of the plant Coleus forskohlii (Briq.), a member of the mint family (Lamiaceae). It is pharmacologically distinguished by its unique ability to directly activate the enzyme adenylyl cyclase (adenylate cyclase), causing a broad elevation of intracellular cyclic adenosine monophosphate (cAMP) across a wide variety of cell and tissue types. Forskolin is used in the treatment of glaucoma and heart failure based on its activity as a cyclic AMP booster. It has also been extensively investigated as a research tool, a dietary supplement for body composition and weight management, and an ingredient in ophthalmic preparations.

Identity and Botanical Classification

Botanical Source and Taxonomy

Coleus forskohlii is a perennial, small member of the mint (Labiatae) family. It grows on sun-exposed, dry hill slopes between an altitude of 1,000 and 6,000 feet in subtropical and temperate climatic zones, and is thus found in India, Nepal, Sri Lanka, and Thailand. Native to the subtropical regions of India and Nepal, this creeping perennial herb features hairy stems and bright pink to purple blooms.

The plant is also known by the synonym Plectranthus barbatus, and the root/rhizome is standardized to a percentage of the labdane diterpene forskolin (C₂₂H₃₄O₇), the primary bioactive molecule. Out of the approximately 300 species of Coleus, only Coleus forskohlii contains the diterpene forskolin.

The Latin genus name comes from the word coleos, which means "sheath" and refers to the fused filaments that form a sheath around the stylus of the flower. The epithet forskohlii commemorates the Finnish botanist Forskal, who traveled extensively in Egypt and Arabia in the eighteenth century. Alternative names for the plant and its extract include Indian coleus, makandi (Ayurvedic), pashanabhedi, coleonol, and forskolin (the isolated diterpene).

Chemical Identity

Forskolin is a polyoxygenated labdane diterpene with multiple chiral centers and an acetate ester; stereochemistry is essential for its activity. The complex chemical structure of forskolin features a decalin core, characteristic of labdane-type diterpenoids, a tetrahydropyran ring, five oxidized positions, and eight chiral centers. Its molecular formula is C₂₂H₃₄O₇, and its systematic IUPAC-related name is 7β-acetoxy-8,13-epoxy-1α,6β,9α-trihydroxy-labd-14-ene-11-one. Chemically, it is classified as a labdane diterpenoid, an acetate ester, an organic heterotricyclic compound, a triol, a cyclic ketone, and a tertiary alpha-hydroxy ketone.

In 1974, forskolin was discovered during a large-scale screening of medicinal plants by the Indian Central Drug Research Institute. The screening revealed the presence of a hypotensive and spasmolytic component, which was initially named coleanol; additional investigation determined the exact chemical structure, and the name was changed to forskolin.

Minor Phytoconstituents

The roots of C. forskohlii contain numerous related secondary metabolites beyond forskolin itself. Other minor diterpenes such as 9-deoxyforskolin, deacetylforskolin, 9-dideoxy-7-deacetylforskolin, and 1,9-dideoxy-7-deacetylforskolin have been isolated from the root extract. Additionally, novel labdane diterpene glycosides, including forskoditerpenoside C–E, and a novel labdane diterpene, forskoditerpene A, were isolated from the ethanolic extract of the whole plant. The plant also contains abietane diterpenoids, 8,13-epoxy-labd-14-en-11-one-diterpenoids, and an essential oil with bornyl acetate as the major compound. There is evidence that other components within the plant extract may have biological activity, as well as enhance the absorption and action of forskolin itself.

Commercial Production and Forms

Commercial production of forskolin relies exclusively on extraction from its only known natural source, the plant Coleus forskohlii, in which forskolin accumulates in the root cork. Extraction from roots/rhizomes uses organic solvents (ethanol/methanol), with subsequent partitioning and purification; commercial products are standardized to a declared percentage of forskolin.

Commercially available preparations include:

• Standardized root extracts: The most common dietary supplement form. Coleus supplements are typically standardized to 10–20% forskolin.
• Ophthalmic solutions: Approved applications of forskolin range from alleviation of glaucoma (Ocufors eye drop solutions, Sabinsa, India), and 1% topical eye drops have been evaluated in open-label clinical trials.
• Intravenous pharmaceutical derivative: Treatment of hypertension and heart failure using colforsin daropate hydrochloride, a water-soluble derivative of forskolin (Nippon Kayaku, Japan).
• Oral capsules: Used in clinical trials and marketed as dietary supplements for weight management and metabolic support.

Traditional and Historical Use

Coleus forskohlii has a long history of use in Ayurvedic, Siddha, and Unani systems of medicine. Ancient Hindu Ayurvedic texts described the use of extracts from Coleus species.

In Ayurvedic medicine, Coleus forskohlii — known traditionally as Makandi or Pashanabhedi — has been used for centuries to support heart health, respiratory function, and urinary tract conditions. Ancient Ayurvedic texts describe it as a remedy for chest pain (angina), hypertension, intestinal spasm, and convulsions. It was also used to dissolve urinary stones, treat fevers, and improve circulatory vigor.

Coleus forskohlii has been used for centuries in Ayurvedic medicine to treat various diseases such as underactive thyroid, heart disease, and respiratory disorders. Its root has also been used in traditional Indian medicine for the treatment of cardiovascular diseases, hypertension, and abdominal pain.

In terms of traditional preparation methods, the plant was typically administered as a decoction of the root or prepared as a herbal powder mixed with ghee or honey. Traditionally, practitioners used the tuberous roots and basal stem segments, prized for their high forskolin content; these underground parts, when dried and ground, served as the basis for powders, decoctions, and extracts.

Gandira's story in Ayurveda stretches back over two millennia, with early Ayurvedic citations appearing in the Bhavaprakasha Nighantu (circa 16th century CE), where it is praised for promoting healthy respiration and balancing Kapha dosha. C. forskohlii has historical applications supporting cardiovascular, hepatic, gastrointestinal, pulmonary, immune, and cognitive function.

Modern scientific interest in Coleus forskohlii began in the 1970s, when Indian researchers isolated forskolin and identified its unique action on cAMP. From 1981 to 2010, forskolin was used in more than 15,000 in vitro and in vivo experimental studies designed to better understand the cellular processes governed by cyclic adenosine monophosphate (cAMP).

Active Constituents and Mechanisms of Action

Primary Active Compound: Forskolin

Forskolin has a unique property of activating almost all hormone-sensitive adenylate cyclase enzymes in a biological system. As initially shown by Seamon and Daly, the diterpene forskolin directly activates adenylyl cyclase (AC) and raises cyclic AMP levels in a wide variety of cell types.

Forskolin would appear to activate adenylate cyclase through a unique mechanism involving both direct activation of the enzyme and facilitation or potentiation of the modulation of enzyme activity by receptors or the guanyl nucleotide-binding subunit, or both. Forskolin is thought to act on the catalytic subunit and also on the coupling mechanism of guanine regulatory sites (Ns and Ni) with the catalytic subunit. It is now clear that forskolin elicits physiological responses which have been shown to be cAMP-dependent.

Forskolin resensitizes cell receptors by activating the enzyme adenylyl cyclase and increasing the intracellular levels of cAMP. Importantly, this activation occurs independently of upstream receptor-ligand signaling — a property that makes forskolin pharmacologically distinctive from hormones or neurotransmitters that act through G-protein–coupled receptors to induce the same pathway. Forskolin causes a rapid and readily reversible elevation of cyclic AMP in rat cerebral cortical slices that is not blocked by a variety of neurotransmitter antagonists.

Downstream Effects of cAMP Elevation

The elevation of cAMP by forskolin triggers a cascade of downstream effects across multiple organ systems:

• Lipolysis and fat metabolism: Forskolin acts directly on adenylate cyclase to produce the second messenger cAMP, which then stimulates the breakdown of fat in human and animal fat cells. Elevated cAMP can activate hormone-sensitive lipase (HSL) in adipocytes (fat cells), which helps release stored fatty acids; those fatty acids then enter mitochondria to be oxidized (burned) for energy.
• Cardiovascular effects: Forskolin may lower blood pressure by relaxing blood vessels and improving blood flow, which can benefit those with hypertension. Additionally, it may enhance heart muscle contractility, as cAMP plays a role in heart muscle contraction.
• Smooth muscle relaxation: In addition to smooth muscle relaxant properties, forskolin also exerts activity on inflammatory mediators, including interleukins and histamine, and on calcium ion influx, leading to its evaluation in asthma.
• Platelet function: Laboratory experiments demonstrate that forskolin inhibits platelet aggregation.
• Intraocular pressure: The ciliary body of the eye depends partly on aqueous humor dynamics; forskolin's cAMP effect can reduce aqueous humor production, which helps explain its presence in 1% ophthalmic solutions studied for open-angle glaucoma.
• Hormone and thyroid stimulation: Forskolin has a role as a protein kinase A agonist, an adenylate cyclase agonist, an antihypertensive agent, and a platelet aggregation inhibitor.
• CYP enzyme induction: Forskolin can induce CYP3A gene expression and potentially increase the metabolism of drugs that are substrates of related microsomal enzymes.

Pharmacokinetic Limitations

Poor solubility and rapid metabolism limit the systemic pharmacokinetic performance of forskolin. Its lipid-soluble nature means it readily crosses cell membranes, but it presents challenges for oral bioavailability and formulation. When forskolin was first discovered, it was poorly soluble in water, and its clinical application as an injection was limited. This limitation spurred development of the water-soluble pharmaceutical derivative colforsin daropate.

Scientific Evidence by Area of Use

1. Body Weight and Body Composition

The most extensively studied area of human clinical application for oral forskolin supplementation is body composition and weight management. Evidence in this area is mixed, limited to small trials, and generally preliminary.

Men — Godard et al. (2005): Thirty subjects (forskolin, n = 15; placebo, n = 15) were studied in a randomized, double-blind, placebo-controlled study for 12 weeks. Forskolin was shown to elicit favorable changes in body composition by significantly decreasing body fat percentage (BF%) and fat mass (FM) as determined by DXA compared with the placebo group (p ≤ 0.05). Additionally, forskolin administration resulted in a change in bone mass for the 12-week trial compared with the placebo group (p ≤ 0.05). There was a trend toward a significant increase for lean body mass in the forskolin group compared with the placebo group (p = 0.097). Serum free testosterone levels were significantly increased in the forskolin group compared with the placebo group (p ≤ 0.05). The primary dose used was 250 mg of 10% forskolin extract twice per day.

Women — Henderson et al. (2005): A parallel 12-week double-blind placebo-controlled trial was conducted in mildly overweight women. In a double-blind and randomized manner, 23 females supplemented their diet with 250 mg of 10% Coleus forskohlii extract (n = 7) or a placebo (n = 12) two times per day for 12 weeks, with body composition assessed by DEXA. Results suggest that Coleus forskohlii does not appear to promote weight loss but may help mitigate weight gain in overweight females, with apparently no clinically significant side effects. There were no significant differences in body weight, bone mineral area, bone mineral density, fat mass, lean mass, % body fat, or % body water observed between the two groups.

Open-label trial — Kamohara & Noparatanawong (2013): Fifteen healthy volunteers participated in an 8-week open-label study in which subjects received 500 mg of Coleus forskohlii extract (10% forskolin) twice a day with their meals, with body composition measurements conducted using a bioelectric impedance analyzer once each week.

Systematic review (2016): A comprehensive review identified 7 clinical studies; of those, 4 were randomized, double-blind, placebo-controlled studies and the others were open-label studies. The C. forskohlii extract showed a significant benefit on body composition in overweight/obese subjects, and no major adverse events were reported. However, the same review noted that additional trials with high quality are required to establish a high level of evidence for the appropriate use of C. forskohlii.

NIH assessment: An NIH Office of Dietary Supplements review notes that Coleus forskohlii (forskolin) has only been studied in a few short-term clinical trials, with current evidence showing no clear effect on body weight and limited safety data, underscoring the need for more rigorous research.

Evidence strength: Preliminary and mixed. The most robust positive signal comes from one small (n = 30) double-blind RCT in men showing reductions in fat mass and increases in free testosterone; a parallel women's trial did not replicate fat-loss findings. All available trials are small, short-term (≤ 12 weeks), and methodologically heterogeneous. Only a handful of clinical trials have looked at the effects of Coleus forskohlii in humans.

2. Glaucoma and Intraocular Pressure

Ophthalmic application of forskolin — particularly as topical eye drops — represents one of the areas with the most direct clinical translation.

Forskolin has been used in animal and limited clinical studies in glaucoma, with only temporary effects reported. A systematic review and meta-analysis identified 3 randomized controlled trials using forskolin-containing combination products that demonstrated strong reductions in intraocular pressure; however, no studies were included that used forskolin alone.

A large open-label Indian study evaluated 1% forskolin eye drops. Ninety adult male/female patients aged 18–60 years suffering from open-angle glaucoma with an intraocular pressure (IOP) of more than 24 mmHg were enrolled. The study on forskolin 1% eye drops confirmed the efficacy of the product over a large sample size, and indicated it could be an alternative in asthmatic patients with glaucoma who are contraindicated for conventional beta-blockers. The results demonstrated the efficacy of 1% forskolin (2 drops thrice a day) in achieving fast onset of action and uniformity of hypotensive activity.

Topical 1% forskolin eye drops have reduced intraocular pressure (IOP) in open-angle glaucoma across several small clinical studies.

Evidence strength: Moderate for IOP reduction via topical eye drops in open-angle glaucoma; the systematic review evidence is based on combination products rather than pure forskolin alone. Oral supplementation for this indication has not been adequately studied. The ophthalmic application is the area closest to an approved clinical use, with regulatory clearance in India.

3. Asthma and Respiratory Function

Forskolin may help alleviate asthma by relaxing lung muscles, leading to bronchodilation, improving breathing, and reducing asthma attacks. Preclinical work showed that in guinea pigs, forskolin blocked bronchospasm caused by inflammatory mediators (histamine, leukotriene-4) and antigens, and relaxation of the bronchioles was also demonstrated in isolated ovine tissue.

The main human clinical evidence comes from a single-blinded trial by González-Sánchez et al. (2006): To determine the efficacy of forskolin in preventing asthma attacks, a single-blinded clinical study was performed in children and adult outpatients at a public hospital in Mexico. Forty patients of either sex with mild persistent or moderate persistent asthma were assigned randomly to 6 months of treatment with forskolin at 10 mg/day orally (capsules) or with two inhalations of sodium cromoglycate every 8 hours. The number of patients who had asthma attacks during the treatment period was significantly lower among those receiving forskolin (8/20, 40%) than among those receiving sodium cromoglycate (17/20, 85%).

Evidence strength: Weak to preliminary for oral use in asthma. Only limited single-blinded clinical studies have been conducted with oral and inhaled forskolin in patients with asthma and in healthy volunteers. The available trial is single-blinded (not double-blinded), has a small sample, and used an active comparator (sodium cromoglycate) rather than a placebo. More rigorous trials are needed.

4. Cardiovascular Function

Forskolin's cardiovascular effects have been studied primarily through its water-soluble pharmaceutical derivative, colforsin daropate hydrochloride (marketed as Adehl in Japan), rather than as an oral dietary supplement.

Colforsin was prepared as a water-soluble forskolin derivative and became available in 1999. Colforsin has been tested on human patients with congestive heart failure, and it improved their hemodynamics. Colforsin daropate is a forskolin derivative that directly activates adenylate cyclase in cardiomyocytes and vascular smooth muscle without mediating the catecholamine beta-adrenoceptor. As with dobutamine, a catecholamine beta agonist, colforsin increases cardiac contractility and reduces peripheral vascular resistance.

In clinical studies, colforsin daropate improved hemodynamics, subjective and objective symptoms of heart failure patients, and was also effective in catecholamine-resistant heart failure patients. It is the first clinically available adenylate cyclase activator.

Results suggest that colforsin daropate may be preferable in the treatment of severe heart failure where the coronary blood flow is reduced and the β-adrenoceptor-dependent signal transduction pathway is down-regulated.

Although anti-inflammatory and blood-pressure lowering effects have been shown in the laboratory setting, very few clinical trials have been conducted using native oral forskolin for cardiovascular indications specifically.

Evidence strength: The intravenous pharmaceutical derivative colforsin daropate has documented clinical evidence for acute heart failure in Japan, where it is an approved drug. Evidence for oral C. forskohlii extract or pure oral forskolin for cardiovascular indications is limited to laboratory and preclinical data; clinical trials using the dietary supplement form are lacking.

5. Metabolic Syndrome and Lipid Profile

One randomized, double-blind placebo-controlled clinical trial assessed metabolic effects in overweight and obese subjects. This study assessed the effects of supplementation with C. forskohlii extract on key markers of obesity and metabolic parameters in overweight and obese individuals; thirty participants completed the trial and were randomly assigned to receive either 250 mg of C. forskohlii extract (n = 15) or a placebo twice daily for 12 weeks, with all participants advised to follow a hypocaloric diet throughout the study. The study measured body weight, BMI, waist and hip circumference, plasma lipids, ghrelin, leptin, glucose, and insulin. Limited studies have shown that Coleus forskohlii extract may aid in weight management in this context.

Evidence strength: Preliminary. The trials showing metabolic benefits are small, short-term, and often conducted in the context of dietary co-intervention, making it difficult to attribute effects solely to forskolin.

6. Testosterone and Bone Density

The Godard et al. (2005) RCT in men also documented hormonal changes: Serum free testosterone levels were significantly increased in the forskolin group compared with the placebo group (p ≤ 0.05). Additionally, forskolin administration resulted in a change in bone mass for the 12-week trial compared with the placebo group (p ≤ 0.05). These effects are mechanistically plausible because Leydig cells in the testes are responsive to cAMP signaling for steroidogenesis.

Extremely limited research suggests that forskolin may increase testosterone and bone mineral density.

Evidence strength: Very preliminary. Based on a single small RCT (n = 15 active, n = 15 placebo). These findings have not been independently replicated in men, and corresponding data in women are absent.

7. Urinary Tract and Antibacterial Effects

Preclinical data suggest additional mechanisms. Treatment of uropathogenic E. coli-infected mice with forskolin reduced bacteria. These findings remain in the realm of animal studies only, and no adequate human clinical evidence exists for urinary tract applications.

8. Research Pharmacology Tool

Beyond therapeutic applications, from 1981 to 2010, forskolin was used in more than 15,000 in vitro and in vivo experimental studies designed to better understand the cellular processes governed by cyclic adenosine monophosphate (cAMP). Labeled forskolin has been used as a means to quantitate the number of adenylyl cyclase molecules, with results documenting that AC expression stoichiometrically limits cyclic AMP formation by hormones and neurotransmitters. This widespread use as a research tool — rather than as a therapeutic agent — accounts for the large volume of published literature that predates clinical dietary supplement studies.

Body Systems and Health Areas of Association

Forskolin's broad mechanism of action — elevation of intracellular cAMP across many tissue types — means it has been investigated in connection with a wide range of body systems:

• Cardiovascular system: Vasodilation, blood pressure reduction, positive inotropy, platelet aggregation inhibition, heart failure (via colforsin daropate).
• Respiratory system: Bronchodilation, smooth muscle relaxation in airways, potential reduction of asthma attack frequency.
• Ophthalmic system: Reduction of intraocular pressure in open-angle glaucoma via aqueous humor modulation.
• Endocrine system: Stimulation of thyroid adenylate cyclase, potential augmentation of testosterone synthesis via Leydig cell cAMP pathways.
• Adipose tissue / metabolic system: Lipolysis via hormone-sensitive lipase activation, body fat percentage reduction, possible attenuation of weight gain.
• Musculoskeletal system: Preliminary evidence of increased bone mass; trend toward lean mass preservation.
• Immune/inflammatory system: Laboratory evidence of effects on interleukins and histamine; anti-inflammatory signaling through cAMP pathways.
• Dermatological system: Therapeutic opportunities were suggested in animal tests, where forskolin-induced pigmentation of the skin, increasing protection against UV-associated carcinogenesis.

Dosage Forms and Doses Reported in Studies

The following dosages reflect those used in published research or pharmaceutical applications and are reported strictly as documented in sources:

• Oral supplementation (body composition, most clinical trials): Most clinical trials have administered 250 mg of Coleus forskohlii extract standardized to contain 10% forskolin twice per day, for a total daily dose of 500 mg of Coleus forskohlii extract, equivalent to 50 mg of forskolin per day.
• Oral supplementation (asthma trial, González-Sánchez et al.): Forty patients were assigned to 6 months of treatment with forskolin at 10 mg/day orally (capsules).
• Open-label body composition trial: Subjects received 500 mg of Coleus forskohlii extract (10% forskolin) twice a day with their meals for 8 weeks.
• Ophthalmic (glaucoma): 1% forskolin eye drops administered as 2 drops thrice a day in an Indian open-label study. Subsequent work revealed that forskolin is effective in reducing IOP even at lower strengths (0.15%), and a randomized, double-blind, clinical trial was initiated in India with forskolin 0.15%.
• Intravenous pharmaceutical (colforsin daropate for heart failure): A colforsin daropate continuous infusion at a rate of 0.7–1.0 μg·kg⁻¹·min⁻¹ for 10–20 minutes followed by 0.5 μg·kg⁻¹·min⁻¹ was recommended to obtain an effective concentration within 10–20 minutes and to maintain a therapeutic concentration.

Safety Considerations and Drug Interactions

General Safety Profile in Clinical Trials

No major adverse events were reported in the clinical trials reviewed in a 2016 systematic review of body composition studies. Coleus forskohlii does not appear to promote weight loss but may help mitigate weight gain in overweight females with apparently no clinically significant side effects.

Forskolin is used in Ayurvedic medicine for various conditions, but clinical studies that demonstrate its safety and effectiveness are lacking. Although anti-inflammatory and blood-pressure lowering effects have been shown in the laboratory setting, very few clinical trials have been conducted. In addition, only a few studies actually use forskolin as an oral supplement, and more studies are needed to determine safety and effectiveness for various conditions in humans.

Blood Pressure Interactions

Laboratory experiments of forskolin suggest hypotensive effects, though clinical relevance has yet to be determined. Concomitant use with medications such as beta-blockers, vasodilators, and/or calcium channel blockers may result in low blood pressure (hypotension).

Anticoagulant and Antiplatelet Interactions

Laboratory studies show that forskolin may have antiplatelet effects similar to those of blood thinners such as warfarin. Therefore, it may have added effects with these medications, increasing the risk of bleeding or bruising. However, clinical relevance has yet to be determined.

A pharmacokinetic study in mice (Pu et al., 2012) added important nuance: Coleus forskohlii extract (CFE) attenuates the anticoagulant action of warfarin by inducing hepatic CYP2C; thus, caution is required with the combination of warfarin and dietary supplements containing CFE. CFE directly inhibited CYP2C activity in mouse and human liver microsomes in vitro, whereas isolated forskolin was only slightly inhibitory, suggesting the whole extract may exert different interactions than isolated forskolin.

CYP Enzyme Interactions

Forskolin can induce CYP3A gene expression and potentially increase the metabolism of drugs that are substrates of related microsomal enzymes, though clinical relevance has yet to be determined.

Gastrointestinal Effects

Increased cAMP tends to stimulate gastric acid secretion, which may explain reports of heartburn or loose stools associated with forskolin use.

Contraindications Identified in Sources

Simultaneous use is contraindicated with anticoagulants, antihypertensives, and vasodilators, or in individuals suffering from ulcers, diabetes, or who are pregnant or breastfeeding. Forskolin should also be avoided in polycystic kidney disease. The safety of forskolin in pregnant and breastfeeding women is not known, so they should avoid it.

Drug Interaction Profile (from Medscape/RxList)

Forskolin may cause bleeding due to additive platelet inhibition when combined with anticoagulant or thrombolytic agents. Aspirin/citric acid/sodium bicarbonate and forskolin both increase anticoagulation (use caution/monitor). Forskolin increases the effects of acarbose by pharmacodynamic synergism, indicating potential for enhanced blood glucose-lowering effects with antidiabetic agents.

Pharmaceutical Derivative: Colforsin Daropate

A notable distinction in the forskolin literature is the development and clinical use of colforsin daropate hydrochloride (also known as NKH477), a water-soluble pharmaceutical derivative. Colforsin daropate hydrochloride is a water-soluble forskolin derivative for the treatment of acute heart failure; like forskolin, it stimulated adenylate cyclase directly and produced pharmacologic activities accompanied by the increase in cellular cAMP. It differs from forskolin in water-solubility, duration of action, blood-brain barrier permeability, oral activity, and adenylyl cyclase subtype selectivity. Colforsin daropate is an inodilator with positive inotropic and vasodilator effects and was effective on a beta-receptor-desensitized heart model in which the effects of beta-agonists and phosphodiesterase inhibitors were attenuated. It improved cardiac function in some heart failure models.

Colforsin daropate hydrochloride is reported as an ingredient of Adehl in Japan and is used for the treatment of acute heart failure. It is capable of directly stimulating adenylate cyclase, causing vasorelaxation via elevated intracellular concentrations of cyclic adenosine monophosphate, making it a useful therapeutic tool in treating cerebral vasospasm.

This pharmaceutical derivative illustrates that the core mechanism of forskolin has been successfully translated into an approved clinical drug, even while oral dietary supplement applications of the parent molecule remain investigational.

Summary of Evidence Quality

• Mechanism of action (adenylyl cyclase activation, cAMP elevation): Well-established across thousands of in vitro and in vivo studies; not in dispute.
• Glaucoma (topical ophthalmic): Moderate evidence from small open-label trials and combination-product RCTs; an approved pharmaceutical application exists in India. Requires more well-controlled trials using forskolin alone.
• Body composition in men: Preliminary positive signal from one small RCT; not replicated in women and not confirmed for weight loss per NIH ODS assessment.
• Asthma (oral): Preliminary; one single-blinded active-comparator trial with positive results; larger double-blind placebo-controlled trials needed.
• Cardiovascular (oral supplement): Largely preclinical; the pharmaceutical derivative colforsin daropate has clinical and pharmacological approval in Japan for acute heart failure.
• Testosterone, bone density: Very preliminary; single small RCT only.
• Safety data: Limited from clinical trials; meaningful drug interactions (anticoagulants, antihypertensives, CYP enzymes) identified primarily from laboratory and pharmacokinetic studies, with uncertain clinical magnitude.

References

• Andersen-Ranberg J et al. "Total biosynthesis of the cyclic AMP booster forskolin from Coleus forskohlii." eLife, 2017. PMC5388535
• ScienceDirect Topics: Forskolin — Overview
• Alasbahi RH, Melzig MF. "Forskolin: from an ayurvedic remedy to a modern agent." Pharmazie, 2007. PubMed 17345261
• Godard MP, Johnson BA, Richmond SR. "Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men." Obesity Research, 2005. PubMed 16129715
• Henderson S et al. "Effects of Coleus Forskohlii Supplementation on Body Composition and Hematological Profiles in Mildly Overweight Women." J Int Soc Sports Nutr, 2005. PMC2129145
• Loftus HL et al. "Coleus forskohlii Extract Supplementation in Conjunction with a Hypocaloric Diet Reduces the Risk Factors of Metabolic Syndrome in Overweight and Obese Subjects: A Randomized Controlled Trial." Nutrients, 2015. PMC4663611
• Arun N et al. "An evidence-based review: Anti-obesity effects of Coleus forskohlii." ScienceDirect, 2016.
• González-Sánchez R et al. "Forskolin versus sodium cromoglycate for prevention of asthma attacks: a single-blinded clinical trial." J Int Med Res, 2006. PubMed 16749416
• Ravindra MS et al. "Efficacy and safety of 1% forskolin eye drops in open angle glaucoma — An open label study." PMC4487936
• Memorial Sloan Kettering Cancer Center: Forskolin — Integrative Medicine Herb Summary
• Patel TB et al. "Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling." Cell Signal, 2003. PubMed 12825829
• Seamon KB, Daly JW. "Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells." Proc Natl Acad Sci USA, 1981. PMC319568
• Hosono M. "Cardiovascular effects of colforsin daropate hydrochloride, a novel drug for the treatment of acute heart failure." Nihon Yakurigaku Zasshi, 1999. PubMed 10511949
• Yoneyama M et al. "Cardiovascular and Adenylate Cyclase Stimulating Effects of Colforsin Daropate." Circ J, 2002.
• Pu et al. "Hepatic cytochrome P450 mediates interaction between warfarin and Coleus forskohlii extract in vivo and in vitro." Br J Pharmacol, 2012. PubMed 23146043
• Murray MT. "Coleus forskohlii." Musculoskeletal Key (chapter from textbook).
• Kamohara S, Noparatanawong S. "A Coleus forskohlii extract improves body composition in healthy volunteers: An open-label trial." Personalized Medicine Universe, 2013.
• Examine.com: Coleus forskohlii — Supplements summary with evidence ratings.
• Bhardwaj R et al. "Forskolin in modern therapeutics: Pharmacology, disease targets, and drug delivery innovations." ScienceDirect, 2026.
• Singh R et al. "Biotechnological interventions for the production of forskolin, an active compound from the medicinal plant Coleus forskohlii." PubMed 38623169
• PMC8000574: "Effect of Forskolin on Body Weight, Glucose Metabolism and Adipocyte Size of Diet-Induced Obesity in Mice." PMC, 2021.
• Drugs.com Natural Product Database: Forskolin — Uses, Benefits & Dosage.